ArticleiScience2026
Prognostic value of radiation treatment time deviation in nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examines the prognostic impact of radiotherapy interruptions (RTIs) on nasopharyngeal carcinoma (NPC), comparing outcomes between continuous and interrupted radiotherapy (RT). A retrospective cohort of 2,059 patients with NPC treated with intensity-modulated radiotherapy (IMRT) from 2017 to 2019 was analyzed. Survival outcomes were assessed using Kaplan-Meier curves and log rank tests. Recursive partitioning analysis (RPA) determined optimal thresholds for radiation treatment time (RTT) and RTT deviation (ΔRTT). Univariate and multivariate Cox proportional hazards models identified independent prognostic factors for overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFFS), and distant metastasis failure-free survival (DMFFS). RPA established RTT and ΔRTT thresholds of 50 and 7 days, respectively; exceeding either threshold was associated with significantly inferior outcomes across all endpoints. Multivariate analysis confirmed ΔRTT as an independent prognostic factor for all endpoints (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.